{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T09:45:26Z","timestamp":1761126326430},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2002,2,1]]},"DOI":"10.1038\/sj.bmt.1703297","type":"journal-article","created":{"date-parts":[[2002,9,5]],"date-time":"2002-09-05T18:19:43Z","timestamp":1031249983000},"page":"S14-S17","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphoma"],"prefix":"10.1038","volume":"29","author":[{"given":"NL","family":"Berinstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Buckstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Imrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Spaner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Mangel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Tompkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Pennell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Pavlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Couvadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2002,2,12]]},"reference":[{"key":"BF1703297_CR1","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","volume":"311","author":"SJ Horning","year":"1984","unstructured":"Horning SJ, Rosenberg SA . The natural history of initially untreated low-grade non-Hodgkin's lymphomas New Engl J Med 1984 311: 1471 1475","journal-title":"New Engl J Med"},{"key":"BF1703297_CR2","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/(SICI)1097-0142(19970315)79:6<1234::AID-CNCR24>3.0.CO;2-#","volume":"79","author":"L Baldini","year":"1997","unstructured":"Baldini L, Guffanti A, Gobbi P et al. A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi Cancer 1997 79: 1234 1240","journal-title":"Cancer"},{"key":"BF1703297_CR3","first-page":"315a","volume":"92","author":"A Hagenbeek","year":"1998","unstructured":"Hagenbeek A, Eghbali H, Monfardini S et al. Fludarabine versus conventional CVP chemotherapy in newly diagnosed patients with stages III and IV low grade non-Hodgkin's lymphoma. Preliminary results from a prospective randomized phase III clinical trial in 381 patients Blood 1998 92: 315a","journal-title":"Blood"},{"key":"BF1703297_CR4","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1182\/blood.V78.12.3275.3275","volume":"78","author":"JG Gribben","year":"1991","unstructured":"Gribben JG, Freedman AS, Woo SD et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment Blood 1991 78: 3275 3280","journal-title":"Blood"},{"key":"BF1703297_CR5","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1200\/JCO.1993.11.7.1344","volume":"11","author":"NL Berinstein","year":"1993","unstructured":"Berinstein NL, Reis MD, Ngan BY et al. Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early-stage and advanced-stage follicular lymphoma J Clin Oncol 1993 11: 1344 1352","journal-title":"J Clin Oncol"},{"key":"BF1703297_CR6","doi-asserted-by":"publisher","first-page":"8910","DOI":"10.1073\/pnas.91.19.8910","volume":"91","author":"Y Liu","year":"1994","unstructured":"Liu Y, Hernandez AM, Shibata D et al. BCL2 translocation frequency rises with age in humans Proc Natl Acad Sci USA 1994 91: 8910 8914","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF1703297_CR7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev.immunol.16.1.395","volume":"16","author":"DT Chao","year":"1998","unstructured":"Chao DT, Korsmeyer SJ . BCL-2 family: regulators of cell death Annu Rev Immunol 1998 16: 395 419","journal-title":"Annu Rev Immunol"},{"key":"BF1703297_CR8","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","volume":"94","author":"AS Freedman","year":"1999","unstructured":"Freedman AS, Neuberg D, Mauch P et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma Blood 1999 94: 3325 3333","journal-title":"Blood"},{"key":"BF1703297_CR9","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood.V91.8.2955.2955_2955_2960","volume":"91","author":"A Lopez-Guillermo","year":"1998","unstructured":"Lopez-Guillermo A, Cabanillas F, McLaughlin P et al. The clinical significance of molecular response in indolent follicular lymphomas Blood 1998 91: 2955 2960","journal-title":"Blood"},{"key":"BF1703297_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1023\/A:1008369623425","volume":"11 (Suppl.\u20091)","author":"A Lopez-Guillermo","year":"2000","unstructured":"Lopez-Guillermo A, Cabanillas F, McLaughlin P et al. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series Ann Oncol 2000 11 (Suppl.\u20091): 137 140","journal-title":"Ann Oncol"},{"key":"BF1703297_CR11","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 1998 16: 2825 2833","journal-title":"J Clin Oncol"},{"key":"BF1703297_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1023\/A:1008395214584","volume":"12","author":"MS Czuczman","year":"2001","unstructured":"Czuczman MS, Grillo-Lopez AJ, McLaughlin P et al. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy Ann Oncol 2001 12: 109 114","journal-title":"Ann Oncol"},{"key":"BF1703297_CR13","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1182\/blood.V83.12.3800.3800","volume":"83","author":"JG Gribben","year":"1994","unstructured":"Gribben JG, Neuberg D, Barber M et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow Blood 1994 83: 3800 3807","journal-title":"Blood"},{"key":"BF1703297_CR14","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood.V81.12.3449.3449","volume":"81","author":"JG Gribben","year":"1993","unstructured":"Gribben JG, Neuberg D, Freedman AS et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma Blood 1993 81: 3449 3457","journal-title":"Blood"},{"key":"BF1703297_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/stem.150297","volume":"15","author":"U Paulus","year":"1997","unstructured":"Paulus U, Dreger P, Viehmann K et al. Purging peripheral blood progenitor cell grafts from lymphoma cells: quantitative comparison of immunomagnetic CD34+ selection systems Stem Cells 1997 15: 297 304","journal-title":"Stem Cells"},{"key":"BF1703297_CR16","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1200\/JCO.1998.16.8.2803","volume":"16","author":"L Fouillard","year":"1998","unstructured":"Fouillard L, Laporte JP, Labopin M et al. Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation \u2013 results of a retrospective analysis on 120 patients autografted in a single institution J Clin Oncol 1998 16: 2803 2816","journal-title":"J Clin Oncol"},{"key":"BF1703297_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0037-1963(00)90057-X","volume":"37 (4 Suppl.\u20097)","author":"JS Horning","year":"2000","unstructured":"Horning JS . Investigation of monoclonal antibody therapy with conventional and high-dose treatment: current clinical trials Semin Hematol 2000 37 (4 Suppl.\u20097): 27 33","journal-title":"Semin Hematol"},{"key":"BF1703297_CR18","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","volume":"63","author":"KC Anderson","year":"1984","unstructured":"Anderson KC, Bates MP, Slaughenhoupt BL et al. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation Blood 1984 63: 1424 1433","journal-title":"Blood"},{"key":"BF1703297_CR19","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 1994 83: 435 445","journal-title":"Blood"},{"key":"BF1703297_CR20","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","volume":"91","author":"D Shan","year":"1998","unstructured":"Shan D, Ledbetter JA, Press OW . Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies Blood 1998 91: 1644 1652","journal-title":"Blood"},{"key":"BF1703297_CR21","doi-asserted-by":"crossref","first-page":"950a","DOI":"10.1182\/blood.V96.3.950","volume":"96","author":"B Coiffier","year":"2000","unstructured":"Coiffier B, Lepage E, Herbrecht R et al. MabThera (rituximab) plus CHOP is superior to chop alone in elderly patients with diffuse large B-cell lymphoma (DLCL): interim results of a randomized GELA trial Blood 2000 96: 950a","journal-title":"Blood"},{"key":"BF1703297_CR22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","volume":"17","author":"MS Czuczman","year":"1999","unstructured":"Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy J Clin Oncol 1999 17: 268 276","journal-title":"J Clin Oncol"},{"key":"BF1703297_CR23","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","volume":"84","author":"DG Maloney","year":"1994","unstructured":"Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma Blood 1994 84: 2457 2466","journal-title":"Blood"},{"key":"BF1703297_CR24","first-page":"115","volume":"5 (Suppl.\u200914)","author":"R Buckstein","year":"1999","unstructured":"Buckstein R, Imrie K, Spaner D et al. Stem cell function and engraftment is not affected by \u2018in vivo purging\u2019 with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma Semin Oncol 1999 5 (Suppl.\u200914): 115 122","journal-title":"Semin Oncol"},{"key":"BF1703297_CR25","first-page":"141a","volume":"94 (Suppl.\u20091)","author":"G Salles","year":"1999","unstructured":"Salles G, Moullet I, Charlot C et al. In vivo purging with rituximab before autologous peripheral blood progenitor cell (PBPC) transplantation in lymphoma patients (pts) Blood 1999 94 (Suppl.\u20091): 141a","journal-title":"Blood"},{"key":"BF1703297_CR26","doi-asserted-by":"crossref","first-page":"384a","DOI":"10.1182\/blood.V96.2.384","volume":"96","author":"C Haioun","year":"2000","unstructured":"Haioun C, Delfau-Larue MH, Beaujean F et al. Efficiency of in vivo purging with rituximab followed by high-dose therapy (HDT) with autologous peripheral blood stem cell transplantation (PBSCT) in B-cell non-Hodgkin's lymphomas (NHL). A single institution study Blood 2000 96: 384a","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1703297","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T22:34:06Z","timestamp":1648074846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1703297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2,1]]},"references-count":26,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2002,2,1]]}},"alternative-id":["BF1703297"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1703297","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2,1]]},"assertion":[{"value":"12 February 2002","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}